Resource Summary Report

Generated by dkNET on Sep 7, 2026

Karpas-422

RRID:CVCL_1325
Type: Cell Line

Proper Citation

RRID:CVCL_1325

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1325

Proper Citation: RRID:CVCL_1325

Description: Cell line Karpas-422 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:1465024, PMID:2297573, PMID:7849311, PMID:8547074, PMID:8558920, PMID:9738977, PMID:12169673, PMID:16960149, PMID:19278952, PMID:19358282, PMID:20164919, PMID:20628145, PMID:23257783, PMID:23292937, PMID:23699601, PMID:25355872, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Characteristics: Quite popular cell line because of its resistance to chemotherapy., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Karpas-422

Synonyms: KARPAS-422, Karpas 422, KARPAS 422, Karpas422, KARPAS422, K422

Cross References: BTO:BTO_0004981, CLO:CLO_0007066, EFO:EFO_0005719, CLDB:cl2996, CLDB:cl4975, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471099,

BioSample:SAMN10988506, cancercelllines:CVCL_1325, Cell_Model_Passport:SIDM01008, ChEMBL-Cells:CHEMBL3308328, ChEMBL-Targets:CHEMBL2366368, Cosmic:907274, Cosmic:1086338, Cosmic:1329088, Cosmic:1629930, Cosmic:1714156, Cosmic:1945182, Cosmic:1995467, Cosmic:2276323, Cosmic:2297003, Cosmic:2361372, Cosmic:2437320, Cosmic-CLP:907274, DepMap:ACH-000315, DSMZ:ACC-32, DSMZCellDive:ACC-32, ECACC:06101702, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS171YVY, ENCODE:ENCBS301UOD, ENCODE:ENCBS530UDH, ENCODE:ENCBS850UIV, ENCODE:ENCBS869AAA, ENCODE:ENCBS870AAA, ENCODE:ENCBS992KXS, GDSC:907274, GEO:GSM115821, GEO:GSM201346, GEO:GSM380129, GEO:GSM552444, GEO:GSM907518, GEO:GSM1035313, GEO:GSM1059807, GEO:GSM1374588, GEO:GSM1669976, GEO:GSM3150249, IARC_TP53:27172, ICLC:HTL99023, LiGeA:CCLE_680, LINCS_LDP:LCL-1120, PharmacoDB:KARPAS422_730_2019, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1325, PubChem_Cell_line:CVCL_1325, Wikidata:Q54899500, Ximbio:152419

ID: CVCL_1325

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260905T180926+0000

Ratings and Alerts

No rating or validation information has been found for Karpas-422.

Warning: Discontinued: DSMZ; ACC-32
Characteristics: Quite popular cell line because of its resistance to chemotherapy., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Molecular oncology, 16(5), 1132.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Science advances, 8(39), eabq0117.

Wenthe J, et al. (2021) Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer immunology, immunotherapy : CII, 70(10), 2851.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Hsu JH, et al. (2020) EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell chemical biology, 27(1), 41.

Bararia D, et al. (2020) Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell reports, 31(5), 107522.

Li M, et al. (2019) Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer cell, 35(6), 916.